Results 11 to 20 of about 243,477 (250)

Discovery platforms for RNA therapeutics [PDF]

British Journal of Pharmacology
: RNA therapeutics are emerging as a unique opportunity to drug currently "undruggable" molecules and diseases. While their advantages over conventional, small molecule drugs, their therapeutic implications and the tools for their effective in vivo ...
Ciucci, Giulio, Zacchigna, Serena, Braga, Luca   +2 more
core   +4 more sources

Antisense RNA Design, Delivery, and Analysis [PDF]

, 2022
This open access volume gathers a variety of models, delivery systems, and approaches that can be used to assess RNA technology for exploiting antisense as a therapeutic intervention.

core   +2 more sources

Contemporary RNA Therapeutics for Glioblastoma [PDF]

NeuroMolecular Medicine, 2021
Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM.
Kaitlyn Melnick, Farhad Dastmalchi, Duane Mitchell, Maryam Rahman, Elias J. Sayour   +4 more
openaire   +2 more sources

RNA-Targeted Therapeutics [PDF]

Cell Metabolism, 2018
RNA-targeted therapies represent a platform for drug discovery involving chemically modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing. Numerous hurdles considered by many to be impassable have been overcome.
Stanley T, Crooke, Joseph L, Witztum, C Frank, Bennett, Brenda F, Baker   +3 more
openaire   +3 more sources

Polymeric carriers for delivery of RNA cancer therapeutics [PDF]

, 2022
As research uncovers the underpinnings of cancer biology, new targeted therapies have been de-veloped. Many of these therapies are small molecules such as kinase inhibitors that target specific proteins, however only 1% of the genome encodes for proteins
Frampton, Adam E., Theoni K. Georgiou, Lythgoe, Mark P, Clark, J, Mark P. Lythgoe, Joana S. Correia, Ottaviani, S, Clark, James, Mirón-Barroso, Sofía, Krel, J, Alexandra Porter, Laura Tookman, Frampton, AE, Salvado Correia, J, Castellano, L, Lythgoe, M, Tookman, L, Georgiou, Theoni K., Frampton, Adam E, Theoni Georgiou, Porter, Alexandra E, James Clark, Tookman, Laura, Alexandra E. Porter, Mirón-Barroso, S, Castellano, Leandro, Georgiou, T, Correia, Joana S., Silvia Ottaviani, Krell, Jonathan, Sofía Mirón-Barroso, Correia, Joana S, Leandro Castellano, Georgiou, Theoni K, Joana Correia, Ottaviani, Silvia, Jonathan Krell, Adam Frampton, Mark Lythgoe, Porter, Alexandra E., Porter, A, Lythgoe, Mark P., Adam E. Frampton   +42 more
core   +1 more source

Formamide significantly enhances the efficiency of chemical adenylation of RNA sequencing ligation adaptors

, 2023
Preadenylated single-stranded DNA ligation adaptors are essential reagents in many next generation RNA sequencing library preparation protocols. These oligonucleotides can be adenylated enzymatically or chemically.
Watts, Jonathan K, Hildebrand, Samuel R, Hedger, Adam K, Khvorova, Anastasia, Yamada, Ken   +4 more
core   +1 more source

Trim25 is an RNA-specific activator of Lin28a/TuT4-mediated uridylation [PDF]

, 2014
RNA binding proteins have thousands of cellular RNA targets and often exhibit opposite or passive molecular functions. Lin28a is a conserved RNA binding protein involved in pluripotency and tumorigenesis that was previously shown to trigger TuT4-mediated
Nowak, Jakub S., Roy Choudhury, Nila, Rappsilber, Juri, Spoel, Steven H, Nila Roy Choudhury, Nowak, Jakub S, Zuo, Juan, Michlewski, Gracjan, Juan Zuo, Juri Rappsilber, Choudhury, Nila Roy, Steven H. Spoel, Gracjan Michlewski, Jakub S. Nowak, Spoel, Steven H.   +14 more
core   +1 more source

RNA Interference by Single- and Double-stranded siRNA With a DNA Extension Containing a 3′ Nuclease-resistant Mini-hairpin Structure [PDF]

, 2013
Selective gene silencing by RNA interference (RNAi) involves double-stranded small interfering RNA (ds siRNA) composed of single-stranded (ss) guide and passenger RNAs.
Jo Milner, Simon J Allison, Milner, J., Allison, Simon J., Milner, Jo   +4 more
core   +1 more source

Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles

, 2021
CRISPR-Cas12a is a leading technology for development of model organisms, therapeutics, and diagnostics. These applications could benefit from chemical modifications that stabilize or tune enzyme properties.
Damha, Masad J, Abdullahu, Leonora, O'Reilly, Daniel, Jana, Sunit, Jensik, Philip J, Ageely, Eman A, Chilamkurthy, Ramadevi, Gagnon, Keith T   +7 more
core   +1 more source

Red blood cell extracellular vesicles as robust carriers of RNA-based therapeutics [PDF]

, 2018
One of the major challenges of RNA-based therapeutics is the method for delivery of RNA molecules. In a recent article (Nat Commun 9(1):2359), we described a novel delivery platform for RNA-based drugs using red blood cell extracellular vesicles which ...
Austin Lam, Minh TN Le, Xin Zhang, Chanh Tin Pham   +3 more
core   +1 more source